Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant
Status:
Withdrawn
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This phase 2 trial studies the side effects and how well midostaurin works in treating older
patients with acute myeloid leukemia with change in genetic material post-hematopoietic cell
transplantation. Midostaruin may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Giving midostaruin post-transplant may improve patient
outcomes.